Related Experiment Video

Updated: Jul 5, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell

Jeong-Seok Nam1, Masaki Terabe, Mizuko Mamura

  • 1Lee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science, Incheon, Korea.

Cancer Research
|May 17, 2008
PubMed

Insights

Transforming growth factor beta (TGF-beta) blockade inhibits breast cancer metastasis by enhancing CD8+ T-cell immunity and tumor cell recognition. This approach offers a promising therapeutic strategy with a favorable safety profile.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Metastasis

Background:

  • Overexpression of transforming growth factor beta (TGF-beta) is linked to cancer metastasis and poor prognosis.
  • TGF-beta antagonism has shown potential in preventing metastasis with minimal toxicity in preclinical studies.

Purpose of the Study:

  • To investigate the underlying mechanisms of anti-TGF-beta antibody efficacy in suppressing breast cancer metastasis using the 4T1 model.
  • To elucidate how TGF-beta blockade impacts the tumor microenvironment and immune response.

Main Methods:

  • Utilized the transplantable 4T1 model of metastatic breast cancer.
  • Administered the anti-TGF-beta antibody 1D11 to assess its effects on metastasis and immune responses.
  • Analyzed changes in immune cell infiltration, activation, and expression of key molecules in tumor cells and the microenvironment.

Main Results:

  • Anti-TGF-beta antibody 1D11 significantly suppressed metastasis by enhancing CD8+ T-cell-mediated antitumor immunity.
  • Treatment increased infiltration and cytotoxic effector function of CD8+ T cells and natural killer cells at metastatic sites.
  • Enhanced expression of NKG2D ligands and death receptors on tumor cells improved immune cell recognition and lysis.

Conclusions:

  • TGF-beta blockade reverses pro-metastatic effects by modulating intercellular interactions within the tumor microenvironment.
  • The synergistic effects on multiple cell compartments contribute to therapeutic efficacy and a potentially wide therapeutic window.
  • Targeting TGF-beta offers a promising strategy for breast cancer treatment by harnessing the immune system to combat metastasis.

More Related Videos

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...